ClearPoint Neuro, Inc. (CLPT)

Over the past six months, Clearpoint Neuro's stock has experienced several notable events and fluctuations, trending up by 37.28%. In January 2026, the company reported preliminary Q4 2025 revenue of approximately $10.4 million, a 20% increase compared to Q4 2024, driven by strong performance in functional neurosurgery disposables and biologics and drug delivery. Also in January 2026, CEO Joseph Burnett sold 20,000 shares of Clearpoint Neuro stock for $322,400.00. In November 2025, the company reported a Q3 2025 loss of $0.21 per share, missing estimates, and revenue of $8.86 million, also falling short of estimates, contributing to a stock decline. Clearpoint Neuro completed the acquisition of IRRAS Holdings in November 2025, which is expected to contribute to the company's growth. In August 2025, Clearpoint Neuro reported record quarterly revenue of $9.2 million for Q2 2025, a 17% year-over-year increase, and entered into a note financing arrangement of up to $105.0 million with Oberland Capital Management. In May 2025, the company reported record Q1 2025 revenue of $8.5 million, an 11% year-over-year increase, with consumable product revenue up, but capital equipment and software revenue decreased.

Specific detailed information regarding the demand seasonality for Clearpoint Neuro, Inc.'s products and services is not readily available. The company's revenue streams may have varying demand patterns that are not explicitly detailed as seasonal in the available information.

Clearpoint Neuro, Inc. is a medical device and therapy-enabling company focused on providing precise navigation and minimally invasive access to the brain and spine. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain, often under MRI guidance. Its major products include the ClearPoint Neuro Navigation System, SmartFrame OR, and Prism Neuro Laser Therapy System. Clearpoint Neuro also provides pre-clinical development services for controlled drug and device delivery. Its business model combines capital equipment sales with recurring revenue from single-use disposables, software, services, and collaborations with biopharma partners.

Clearpoint Neuro, Inc. has a global reach, engaging with healthcare and research centers across North America, Europe, Asia, and South America. The company's headquarters are located in Solana Beach, California, United States. In June 2025, Clearpoint Neuro expanded its operations by signing a lease for approximately 30,171 square feet in San Diego for office and lab use, with occupancy phased from June 2025 through July 2026.

Clearpoint Neuro's brand reputation in the past year is characterized by optimism regarding its growth prospects and some scrutiny related to financial performance and analyst ratings. Analysts have expressed optimism about the company's future, citing its innovative approach to minimally invasive brain surgery and growth prospects. While there is an overall "Moderate Buy" consensus rating from analysts, some firms have issued more cautious ratings. The near-term outlook for Clearpoint Neuro's biopharma business has been clouded by FDA uncertainty surrounding uniQure's AMT-130. The sale of a significant number of shares by CEO Joseph Burnett in January 2026 could be perceived differently by investors.

Clearpoint Neuro, Inc. has a diverse ownership structure, including institutional, retail, and individual investors. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., and Geode Capital Management, Llc. Institutional ownership in Clearpoint Neuro is approximately 41%. The general public, primarily individual investors, collectively holds 51% of Clearpoint Neuro shares, and CEO Joseph Burnett owns 0.8% of the company's shares.